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Abstract: A series of imidazopyrimidine derivatives with the general formula I was synthesized and identified as potent 
inhibitors of iNOS dimer formation, a prerequisite for proper functioning of the enzyme. Stille and Negishi coupling 
reactions were used as key steps to form the carbon-carbon bond connecting the imidazopyrimidine core to the central 
cycloalkenyl, cycloalkyl and phenyl ring templates. 
  Nitric oxide (NO) is involved in many physiological 
processes, such as maintaining vascular tone and homeos-
tasis, mediating neurotransmission, regulating gastrointes-
tinal motility, and enacting host defense in the immune 
system [1-3]. In mammals, nitric oxide (NO) is synthesized 
from L-arginine by a family of NO synthases (NOS). Of the 
three characterized NOS isoforms, the neuronal NOS 
(nNOS) and endothelial NOS (eNOS) are constitutively 
expressed, and under normal physiological conditions, 
generate low levels of NO in response to increases in 
intracellular calcium levels. The third NOS isoform, the 
inducible NOS (iNOS), is calcium-independent, not usually 
expressed under physiological conditions, and is induced by 
endotoxin and/or cytokines, such as lipopolysaccharide 
(LPS), interleukin-1 (IL-1), tumor necrosis factor  (TNF-
) and interferon- (IFN). Once induced, iNOS produces 
high and sustained levels of NO. The overexpression of 
iNOS, and the resulting excessive production of NO which 
results in cellular cytotoxicity and tissue damage, has been 
implicated in the pathogenesis of a number of inflammatory 
diseases, such as rheumatoid arthritis, osteoarthritis, 
inflammatory bowel disease, multiple sclerosis and asthma 
[3-8].
  Therefore, iNOS inhibitors may find utility for the 
treatment of these diseases. Because of the importance of the 
constitutive forms in normal physiology, high selectivity for 
iNOS is advantageous to avoid blocking the basic 
homeostatic functions of the eNOS and nNOS isoforms. The 
three NOS isoforms differ in their location and function, but 
are similar in that they are only active in the dimeric form [9-
11].
 Preventing
 the dimerization of inactive NOS monomers 
into active homodimers has emerged as a novel 
pharmacological strategy to develop isoform-selective NOS 
inhibitors. Highly potent and selective imidazopyri-midine-
based iNOS dimerization inhibitors, exemplified by 
compounds  1 and 2  (Fig.  1),  were discovered recently. 
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These compounds significantly decreased levels of NO 
production [10, 11]. Based on the crystal structure of 2 
bound to murine iNOS monomeric oxygenase domain (iNOS 
114) [12-14], the imidazole group binds to the heme, while 
the benzodioxolane group fits closely between residues in 
the iNOS monomer active site and the pyrimidine ring, 
resulting in a U-shaped conformation of the molecule in its 
active site. This prevents Glu377 of helix 7A from 
occupying the position that leads to dimer formation. Based 
on this binding mode, new inhibitors using alternative 
linkers such as hydroxyethylamine, hydroxypiperidine, 
hydroxypyrimidine, etc, to connect the benzodioxolane and 
imidazole moieties have been reported [12-14].
 As part of 
our research program on new chemical classes of iNOS 
inhibitors, we designed and synthesized a series of 
imidazopyrimidine derivatives with the general formula I 
(Fig. 1) as isosteric analogs of 1 and 2. In the structure of 
these compounds, the central piperazine and pyrrolidine 
heterocycle templates in 1 [10, 11] and 2
 [11]
 were replaced 
with cycloalkenyl, cycloalkyl and phenyl rings. Some of 
these new agents were potent iNOS dimerization inhibitors 
in cell-based iNOS assays. 
 In  compounds  1 and 2, the piperazine and pyrrolidine 
heterocycles are connected to the pyrimidine ring via  a 
carbon-nitrogen (C-N) bond which can be easily formed by a 
simple nucleophilic substitution reaction [14].
  In our 
proposed target molecules, the pyrimidine ring is linked to a 
cycloalkenyl, cycloalkyl or phenyl ring via a carbon-carbon 
(C-C) bond, which was expected to be established through 
palladium-catalyzed coupling reactions. The synthesis of the 
target molecules 3-9 is outlined in Scheme 1. We first 
attempted to prepare these compounds using the palladium-
catalyzed Suzuki coupling as the key step. Condensation of 
the commercially available 2,4-dichloro-6-methylpyrimidine 
(17) with imidazole in acetone in the presence of potassium 
carbonate gave a mixture of regioisomers 18 and 19 easily 
separated by column chromatography [14]. The enol triflates 
21a,b  were  prepared from the  corresponding ketoesters   
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20a,b as reported previously [15]. Palladium catalyzed reaction 
of the enol triflate 21a with bis(pinacolato)diboron
  [16] was 
incomplete after 24 hours at 50 
oC, and furthermore, the desired 
boron derivative 22  could not be separated from  the 
bis(pinacolato)diboron by column chromatography. Prolonging 
the reaction time resulted in a mixture of 22 and the dimer 
resulting from the coupling of 22 with the triflate 21a.  The 
inseparable mixture 22/bis(pinacolato)diboron was then reacted 
with the chloropyrimidine derivative 19 under Suzuki coupling 
conditions. Unfortunately, the reaction produced a complex 
mixture, failing to yield the desired coupling product. An 
alternative route for the preparation of 24a was then designed. 
This involved first converting 19 to the corresponding 
pinacolatoboron intermediate, and then coupling it with the 
triflates  21a under Suzuki coupling conditions. However, 
condensation of 19 with bis(pinacolato)diboron using the same 
reaction condition as for 22 was not successful with no reaction 
observed. With the failure of the Suzuki coupling approach, 
next we tried other alternatives. Palladium-catalyzed reductive 
coupling reaction of chloropyrimidine 19 with methyl 1-
cyclopentene-1-carboxylate using the same reaction condition 
as described in a previous total synthesis of epibatidine [17], 
afforded the deschloro compound, i.e. 2-(1H-imidazol-1-yl)-4-
methylpyrimidine, instead of the desired coupled product 24a. 
Heck reaction of chloropyrimidine 19 with methyl 1-
cyclopentene-1-carboxylate following Fu’s modified method 
using Pd2(dba)3-P(t-Bu)3 as catalyst
  [18] gave no reaction. 
Another alternative approach to secure the C-C bond connecting 
the cycloalkenyl moiety to the pyrimidine core is through the 
Stille coupling method. Treatment of 19  with bis(tributyltin) 
using Pd(Ph3P)2Cl2 as catalyst in DMF furnished the desired tin 
compound 23 in 74% yield. Condensation of 23 with the enol 
triflate derivative 21a under standard Stille coupling reaction 
condition using Pd(PPh3)4 as catalyst in the presence of LiCl in 
refluxing THF
 [19]
 gave no reaction. Changing the solvent from 
THF to dioxane did not result in any improvement. Coupling of 
23 with the triflate 21a also failed with Corey’s modified 
coupling system using Pd(PPh3)4/CuCl/LiCl [20]. Finally we 
found that when the Stille coupling reaction of 23 with the 
triflate  21a  was carried out in DMF at 110 
oC using 
Pd(PPh3)2Cl2 as catalyst, the desired coupling product 24a was 
successfully obtained, although in low yield (~ 10%). Replacing 
Pd(PPh3)2Cl2 with dichlorobis(tri-o-tolylphosphine)palladium 
(II), i.e. Pd[(o-CH3Ph)3P)2]Cl2, moderately improved the yield 
to 16%. To our delight, while using dichlorobis(acetonitrile) 
palladium (II), Pd(CH3CN)2Cl2, which is not a commonly used 
catalyst for Stille coupling, the coupling product 24a  was 
obtained in 38% isolated yield. This catalyst also worked 
efficiently for the coupling of the enol triflate 21b with 23, 
yielding 24b in similar yield. The coupling system we describe 
here, 0.1 equiv Pd(CH3CN)2Cl2 / 6 equiv LiCl / DMF, may have 
potential applications in other difficult cases of Stille coupling 
reactions. With the success of introducing the five-membered 
cyclopentenyl and the six-membered cyclohexenyl groups to 
the pyrimidine ring via C-C bond, the following conversion of 
24a,b to the target molecules was straightforward. Hydrolysis of 
the esters 24a,b with lithium hydroxide afforded the carboxylic 
acids 25a,b, which were coupled with 3,4-methylenedioxyphen-
ethylamine using TBTU [O-(benzotriazol-1-yl)-N,N,N',N'-tetra-
methyluronium tetrafluoroborate] as coupling reagent to yield 
the target molecules 3 and 6, respectively. Hydrogenation of 3 
and  6  gave the double bond reduced cis  analogs  4 and 7, 
respectively. Compounds 4 and 7 were cleanly epimerized to 
the trans analogs 5 and 8 by treatment with DBU in refluxing 
benzene. The synthesis of the target compound 9 was also 
straightforward. The reaction of chloropyrimidine 19 with 2-
ethoxycarbonylphenylzinc bromide in the presence of Pd(PPh3)4 
under Negishi coupling condition afforded the coupled product 
26 in 84% yield. The ester 26 was then converted to the target 
compound 9 in a similar manner as for the synthesis of 3 and 6 
from 24a,b. 
  Next, we made various modifications on the molecule 9 at 
the tether linking the middle phenyl ring to the benzodioxolane 
group to further investigate the SAR of this new chemical 
series. The compounds 10-16 were prepared according to 
Scheme  2. 2-Iodophenylacetic acid (28) was condensed with 
piperonylamine using TBTU as coupling reagent to provide the 
amide 29, which was then coupled with the organotin derivative 
23 using Pd(CH3CN)2Cl2 as catalyst under microwave 
conditions to yield 10. Similar to the preparation of ester 26, 
Negishi coupling of 19 with 2-cyanophenylzinc bromide 
furnished 30 in excellent yield. The cyano derivative 30 was 
then converted to the primary amine 31 by hydrogenation. 
Compound 31 was then converted to the amide 11 using the 
above-mentioned TBTU coupling method, and converted to the 
urea analog 12 by condensation with 3,4-(methylenedioxy) 
phenyl isocyanate. Stille coupling of bromide 33 and 35 with 23 
using the same reaction condition as for 24a,b yielded amide 
13, and sulfonamide 14, respectively. Compounds 15 and 16 
were prepared according to the same reaction conditions 
described above for the synthesis of 9. 
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 The  imidazopyrimidines  3-16 were evaluated for their 
abilities to inhibit cytokine-mediated induction of iNOS 
activity in DLD-1 cells (Tables 1 and 2). The initial strategy 
consisted of replacing the central pyrrolidine group of 2 with 
a cyclopentene moiety. This modification led to a 10-fold 
decrease in the iNOS potency. Hydrogenation of the double 
bond functionality of 3 provided compound 4, which 
displayed similar iNOS potency than its unsaturated analog. 
The cis and trans relative stereochemistry at the cyclopentyl  
 
scaffold did not significantly influence the activity, the iNOS 
potency of the the cis and trans isomers 4 and 5 was within a 
factor of 2. Extending the cyclopentene group of 3 to a 
cyclohexene moiety led to a 2-fold increase in the iNOS 
potency. However, the cis and trans saturated analogs of 6, 
i.e. compounds 7 and 8 respectively, were more than 10-fold 
less potent than 6. Replacement of the cyclohexenyl group of 
6 with a phenyl ring was well tolerated. The phenylpyrimi-
dine derivative 9 had comparable iNOS inhibitory activity as  
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Scheme 1. Reagents and conditions: a) bis(pinacolato)diboron, K2CO3, Pd(PPh3)2Cl2, PPh3, dioxane, 50 
oC; b) imidazole, K2CO3, acetone, 
rt, 37% for 19; c) bis(tributyltin), Pd(PPh3)2Cl2, DMF, 95 
oC, 24 h, 74%; d) 21a, b, Pd(CH3CN)2Cl2, LiCl, DMF, 105 
oC, 72 h, 38% for 24a, 
36% for 24b; e) LiOH, MeOH-THF-H2O, rt, 18 h, 92% for 25a, 88% for 25b, 84% for 27; f) 3,4-methylenedioxyphenethylamine, TBTU, 
iPr2NEt, CH3CN, rt, 48 h, 88% for 3, 92% for 6, 70% for 9; g) H2 (1 atm), Pd/C, rt, 72 h, > 90%; h) DBU, PhH, reflux, 48 h, 90%; i) 2-
ethoxycarbonyl-phenylzinc bromide, Pd(PPh3)4, THF, 50 
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Scheme 2. Reagents and conditions: a) piperonylamine, TBTU, iPr2NEt, CH3CN, rt, 24 h, 98%; b) 23, Pd(CH3CN)2Cl2, LiCl, Et3N, DMF, 
180 
oC, microwave, 1 h, 38%; c) 2-cyanophenylzinc bromide or 3-ethoxycarbonylphenylzinc iodide, Pd(PPh3)4, THF, 50 
oC, 48 h, 94% for 
30, 49% for 36; d) H2 (1 atm), Pd/C, MeOH, HCl, rt, 48 h, 85%; e) 3,4-(methylenedioxy)phenylacetic acid, TBTU, iPr2NEt, CH3CN, rt, 24 
h, 93%; f) 3,4-(methylenedioxy)phenyl isocyanate, Et3N, DCM, rt, 2 h, 91%; g) piperonyloyl chloride, Et3N, DCM, rt, 2 h, 100%; h) 23, 
Pd(CH3CN)2Cl2, LiCl, DMF, 105 
oC, 72 h, 4% for 13, 10% for 14; i) 3,4-methylenedioxyphenethylamine, Et3N, DCM, rt, 1 h, 100%;  j) 
LiOH, MeOH-THF-H2O, rt, 24 h, 86%; k) 3,4-methylenedioxyphenethylamine or 3-benzo[1,3]dioxol-5-yl-propylamine, TBTU, iPr2NEt, 
CH3CN, rt, 48 h, 83% for 15, 20% for 16. 12    The Open Medicinal Chemistry Journal, 2009, Volume 3  Chu et al. 
Table 1.   iNOS  Inhibitory Activity of Compounds 1-9 
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Table 2.  iNOS  Inhibitory Activity of Compounds 10-16 
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its cyclohexenyl analog (6: IC50 = 12 nM; 9: IC50 = 19 nM). 
In order to explore the size of the pocket in which the 
benzodioxolane group of 9 interacts, we prepared various 
analogs of 9 in which the benzodioxolane moiety is 
connected to the 2-(1H-imidazol-1-yl)-4-methyl-6-phenyl-
pyrimidine template by various linkers. As indicated in 
Table  2, replacement of the carbonylaminoethyl linker 
(CONHCH2CH2) of 9 with various chains containing either 
amido (compounds 10,  11,  13) or urea (compound 12) 
functionalities led to a significant decrease in the iNOS 
potency. Similarly, replacing the carboxamide functionality 
of 9 by a sulfonamide group (compound 14) led to a 100-
fold decrease in the iNOS potency. Furthermore, changing 
the ortho-substitution pattern of the central phenyl ring in 9 
to the meta-substitution pattern as in 15 led to a dramatic 
loss of potency. Taken together, these data indicate that the 
structure and the connection pattern of the tether linking the 
central phenyl ring of the 2-(1H-imidazol-1-yl)-4-methyl-6-
phenylpyrimidine to the benzodioxolane group had a 
significant influence on the iNOS potency. The four atom 
amide tether, CONHCH2CH2, connecting to the central 
phenyl ring with an ortho-substitution pattern was the most 
preferred for optimal iNOS inhibitory activity. Modifications 
on this linker were generally detrimental to the potency. 
  In summary, a series of imidazopyrimidine derivatives 3-
16 was synthesized and evaluated to inhibit cytokine-
mediated induction of iNOS activity in DLD-1 cells. Stille 
coupling and Negishi coupling reactions were used as key 
steps to form the C-C bond connection between the 
pyrimidine and the central cycloalkenyl, cycloalkyl and 
phenyl rings. Some of these agents are potent inhibitors of 
iNOS dimer formation, a prerequisite for proper functioning 
of the enzyme in cell-based iNOS assays. Among these, 
compounds  6  and  9, which contain six-membered cyclo-
hexenyl and phenyl rings as central templates, are the most 
potent inhibitors in the new chemical series, displaying IC50 
values of 12 and 19 nM, respectively. These compounds may 
serve as good leads for further analog design, and the 
synthetic methods can provide a general approach to the 
preparation of such compounds. 
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